Sydney, 31 January: Noxopharm Limited announces that its first NOX66 Phase 1a/1b clinical study involving NOX66 has received approval from the Georgian Ministry of Health to begin recruitment.
This first-in-human formal study involves patients with late-stage cancer (breast, ovary, prostate, lung and head and neck) who have failed standard therapies including carboplatin and who have no remaining standard treatment options. NOX66 is being assessed for its ability to overturn the drug- resistance mechanisms developed by cancer cells that enable them to resist all chemotherapy drugs including carboplatin. Apart from seeking to make carboplatin chemotherapy generally more effective, the ultimate objective is to lower chemotherapies such as carboplatin dosages to safer but highly effective levels. The aim is to provide an effective treatment option for patients considered too frail or too elderly to undergo chemotherapy, or for the significant number of cancer patients who currently chose not to undergo further chemotherapy.
For further information please download PDF attached:
Download this document
